MENLO PARK, Calif. – Deepcell, a pioneer in artificial intelligence (AI)-powered single-cell analysis to fuel deep biological discoveries, today announced the appointment of Mark Aitkenhead, Ph.D., to the newly created position of Chief Commercial Officer.
“We are delighted to welcome Dr. Aitkenhead to our leadership team to drive commercial strategy and lead the company’s sales, support, and marketing functions,” said Maddison Masaeli, Ph.D., CEO of Deepcell. “Through his extensive career commercializing life sciences technologies, Mark has consistently shown his ability to develop and lead outstanding commercial teams and his ability to successfully introduce transformative solutions to the market that empower scientists and fuel new discoveries.”
Prior to joining Deepcell, Dr. Aitkenhead was Chief Commercial Officer at Element Biosciences where he built, guided, and managed the customer-facing functions of the company, including sales, marketing, customer support, and training. Prior to Element Biosciences, he held a variety of leadership positions at Thermo Fisher Scientific including General Manager for Cellular Analysis Instrumentation and Global Commercial Leader for the Clinical Next Generation Sequencing (NGS) Division, among others. While at Thermo Fisher, Dr. Aitkenhead also worked in technical and application support, field sales, and global customer care strategy. He received both his Ph.D. in Anatomy and Bachelors in Biomedical Sciences from The Queen’s University of Belfast in Northern Ireland.
“Deepcell has created a truly novel platform leveraging the power of artificial intelligence to scale single cell analysis in ways never thought possible,” said Mark Aitkenhead, Ph.D., Chief Commercial Officer, Deepcell. “I look forward to spearheading the commercial efforts at Deepcell and to bring this innovative technology to researchers around the globe.”
Deepcell is a life science company which brings artificial intelligence to cell biology, unlocking a new field of high-dimensional biological discovery known as morpholomics. Through Deepcell’s AI-powered imaging and microfluidics solution, the REM-I Platform, the company is enabling a new scale of cell biology research and single cell analysis leveraging cellular morphology for unbounded discovery. Deepcell’s platform leverages its artificial intelligence model, the Human Foundation Model, to identify and sort cells based on morphological distinctions helping power basic and translational research and offering future applications in diagnostic testing and therapeutics targeting. The company was spun out of Stanford University in 2017 and has raised nearly $100 million in venture capital. It is based in Menlo Park, California. Learn more at www.deepcell.com or follow us on LinkedIn, Twitter, and YouTube.